Human herpesvirus 6B reactivation and delirium are frequent and associated events after cord blood transplantation | Zendy

Joshua A. Hill | Zendy; Michael Boeckh | Zendy; Wendy M. Leisenring | Zendy; Hu Xie | Zendy; Andrew Adler | Zendy; M-L Huang | Zendy; Jesse R. Fann | Zendy; Colleen Delaney | Zendy; Danielle M. Zerr | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Human herpesvirus 6B reactivation and delirium are frequent and associated events after cord blood transplantation

Author(s) -

Joshua A. Hill,

Michael Boeckh,

Wendy M. Leisenring,

Hu Xie,

Andrew Adler,

M-L Huang,

Jesse R. Fann,

Colleen Delaney,

Danielle M. Zerr

Publication year - 2015

Publication title -

bone marrow transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.609

H-Index - 127

eISSN - 1476-5365

pISSN - 0268-3369

DOI - 10.1038/bmt.2015.154

Subject(s) - medicine , delirium , human herpesvirus 6 , odds ratio , transplantation , hematopoietic stem cell transplantation , hazard ratio , cord blood , confidence interval , prospective cohort study , immunology , herpesviridae , viral disease , intensive care medicine , human immunodeficiency virus (hiv)

Human herpesvirus 6B (HHV-6B) frequently reactivates after cord blood transplantation (CBT). We previously reported an association between HHV-6B reactivation and delirium after hematopoietic cell transplantation. In this prospective study, 35 CBT recipients underwent twice-weekly plasma PCR testing for HHV-6 and thrice-weekly delirium assessment until day 84. There was a quantitative association between HHV-6B reactivation and delirium in univariable (odds ratio, 2.88; 95% confidence interval (CI), 0.97-8.59) and bivariable models. In addition, intensified prophylaxis with high-dose valacyclovir mitigated HHV-6B reactivation (adjusted hazard ratio, 0.39; 95% CI, 0.14-1.08). Larger trials are needed to explore the utility of HHV-6B prophylaxis after CBT.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research